ICU Medical(DE:IC7)
€162.00+3.00 (+1.89%)
DE:IC7
ICU Medical financials statements
€162.00
At close:+3.00 (+1.89%)
ICU Medical (IC7) Ratios
0 Followers
ICU Medical Ratios
DE:IC7's free cash flow for Q3 2026 was $83.40M. For the 2026 fiscal year, DE:IC7's free cash flow was decreased by $-16.19M and operating cash flow was $99.59M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.36 | 2.59 | 2.53 | 2.50 | 5.13 |
| Quick Ratio | 1.13 | 1.54 | 1.06 | 1.09 | 3.68 |
| Cash Ratio | 0.62 | 0.55 | 0.53 | 0.42 | 2.75 |
| Solvency Ratio | 0.10 | -0.05 | 0.09 | 0.07 | 0.76 |
| Operating Cash Flow Ratio | 0.36 | 0.37 | 0.34 | -0.13 | 1.33 |
| Short-Term Operating Cash Flow Coverage | 5.19 | 4.00 | 3.26 | -2.09 | 0.00 |
| Net Current Asset Value | $ -749.24M | $ -796.71M | $ -1.03B | $ -1.19B | $ 765.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.34 | 0.39 | 0.39 | 0.38 | 0.02 |
| Debt-to-Equity Ratio | 0.66 | 0.84 | 0.80 | 0.83 | 0.03 |
| Debt-to-Capital Ratio | 0.40 | 0.46 | 0.45 | 0.45 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.38 | 0.44 | 0.43 | 0.44 | 0.00 |
| Financial Leverage Ratio | 1.91 | 2.14 | 2.06 | 2.16 | 1.16 |
| Debt Service Coverage Ratio | 2.19 | -0.06 | 1.96 | 2.31 | 237.07 |
| Interest Coverage Ratio | 1.01 | 0.40 | 0.22 | -0.61 | 143.64 |
| Debt to Market Cap | 0.38 | 0.42 | 0.68 | 0.44 | 0.00 |
| Interest Debt Per Share | 60.78 | 71.68 | 74.99 | 75.63 | 2.16 |
| Net Debt to EBITDA | 3.51 | 31.03 | 5.73 | 7.96 | -2.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.76% | 34.62% | 32.75% | 30.60% | 37.34% |
| EBIT Margin | 4.87% | 1.70% | 1.08% | -1.91% | 9.43% |
| EBITDA Margin | 13.87% | 1.80% | 11.21% | 8.40% | 16.98% |
| Operating Profit Margin | 4.80% | 1.80% | 1.01% | -1.88% | 9.36% |
| Pretax Profit Margin | 0.14% | -2.77% | -3.47% | -5.02% | 9.36% |
| Net Profit Margin | 0.03% | -4.94% | -1.31% | -3.26% | 7.84% |
| Continuous Operations Profit Margin | 0.03% | -4.94% | -1.31% | -3.26% | 7.84% |
| Net Income Per EBT | 23.10% | 178.28% | 37.87% | 64.93% | 83.72% |
| EBT Per EBIT | 2.96% | -153.64% | -343.04% | 266.70% | 99.95% |
| Return on Assets (ROA) | 0.02% | -2.80% | -0.68% | -1.65% | 5.48% |
| Return on Equity (ROE) | 0.03% | -5.99% | -1.40% | -3.55% | 6.38% |
| Return on Capital Employed (ROCE) | 3.01% | 1.18% | 0.59% | -1.07% | 7.34% |
| Return on Invested Capital (ROIC) | 0.69% | 1.16% | 0.22% | -0.68% | 6.11% |
| Return on Tangible Assets | 0.04% | -5.80% | -1.46% | -3.57% | 6.25% |
| Earnings Yield | 0.02% | -3.11% | -1.23% | -1.98% | 2.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.35 | 11.75 | 12.40 | 9.23 | 10.55 |
| Payables Turnover | 9.14 | 10.52 | 10.13 | 7.33 | 10.17 |
| Inventory Turnover | 2.29 | 2.66 | 2.14 | 2.27 | 2.84 |
| Fixed Asset Turnover | 4.40 | 4.77 | 3.30 | 3.20 | 2.58 |
| Asset Turnover | 0.55 | 0.57 | 0.52 | 0.50 | 0.70 |
| Working Capital Turnover Ratio | 2.85 | 2.93 | 3.05 | 2.91 | 1.70 |
| Cash Conversion Cycle | 148.98 | 133.40 | 163.81 | 150.28 | 127.14 |
| Days of Sales Outstanding | 29.55 | 31.06 | 29.43 | 39.53 | 34.61 |
| Days of Inventory Outstanding | 159.38 | 137.04 | 170.42 | 160.56 | 128.44 |
| Days of Payables Outstanding | 39.95 | 34.69 | 36.04 | 49.81 | 35.90 |
| Operating Cycle | 188.93 | 168.10 | 199.85 | 200.09 | 163.04 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 7.30 | 8.37 | 6.90 | -2.60 | 12.62 |
| Free Cash Flow Per Share | 3.73 | 5.11 | 3.01 | -6.76 | 8.79 |
| Dividend Paid and CapEx Coverage Ratio | 2.04 | 2.57 | 1.77 | -0.63 | 3.30 |
| Capital Expenditure Coverage Ratio | 2.04 | 2.57 | 1.77 | -0.63 | 3.30 |
| Operating Cash Flow Coverage Ratio | 0.13 | 0.12 | 0.10 | -0.04 | 5.94 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.09 | 0.07 | -0.03 | 0.20 |
| Free Cash Flow Yield | 2.61% | 3.29% | 3.02% | -4.30% | 3.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 4803.70 | -32.13 | -81.03 | -50.60 | 48.80 |
| Price-to-Sales (P/S) Ratio | 1.58 | 1.59 | 1.06 | 1.65 | 3.82 |
| Price-to-Book (P/B) Ratio | 1.66 | 1.93 | 1.13 | 1.80 | 3.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 38.29 | 30.36 | 33.13 | -23.28 | 27.01 |
| Price-to-Operating Cash Flow Ratio | 19.55 | 18.55 | 14.46 | -60.50 | 18.81 |
| Price-to-Earnings Growth (PEG) Ratio | -47.74 | -0.11 | 1.34 | 0.31 | 2.90 |
| Enterprise Value Multiple | 14.87 | 119.11 | 15.22 | 27.59 | 20.25 |
| Enterprise Value | 4.60B | 5.12B | 3.85B | 5.28B | 4.53B |
| EV to EBITDA | 14.87 | 119.11 | 15.22 | 27.59 | 20.25 |
| EV to Sales | 2.06 | 2.15 | 1.71 | 2.32 | 3.44 |
| EV to Free Cash Flow | 50.10 | 41.05 | 53.11 | -32.73 | 24.28 |
| EV to Operating Cash Flow | 25.58 | 25.08 | 23.18 | -85.05 | 16.91 |
| Tangible Book Value Per Share | -0.39 | -8.54 | -9.12 | -14.33 | 65.28 |
| Shareholders’ Equity Per Share | 86.19 | 80.58 | 88.14 | 87.56 | 76.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.77 | -0.78 | 0.62 | 0.35 | 0.16 |
| Revenue Per Share | 90.50 | 97.67 | 93.77 | 95.53 | 62.07 |
| Net Income Per Share | 0.03 | -4.83 | -1.23 | -3.11 | 4.86 |
| Tax Burden | 0.23 | 1.78 | 0.38 | 0.65 | 0.84 |
| Interest Burden | 0.03 | -1.63 | -3.21 | 2.62 | 0.99 |
| Research & Development to Revenue | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| SG&A to Revenue | 0.28 | 0.27 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
| Income Quality | 245.69 | -1.73 | -5.60 | 0.84 | 2.59 |
Currency in USD
